Amsterdam, Netherlands

Roeland Lameris

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.2

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Amsterdam, NL (2019 - 2023)
  • Utrecht, NL (2024)

Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Roeland Lameris: Innovator in Antibody Technology

Introduction

Roeland Lameris is a prominent inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody technologies. With a total of 4 patents to his name, Lameris is recognized for his groundbreaking work in the modulation of immune responses.

Latest Patents

Lameris's latest patents include "Single domain antibodies targeting CD1d," which relates to compounds, specifically polypeptides that bind to the non-classical MHC protein CD1d. This invention aims to modulate CD1d-mediated biological functions through the use of single domain antibodies. Another notable patent is "Bispecific antibodies for use in the treatment of hematological malignancies." This invention focuses on novel methods for treating hematological malignancies using antibodies that bind to both human CD1d and the human Vγ9Vδ2-TCR.

Career Highlights

Throughout his career, Roeland Lameris has worked with notable companies such as Lava Therapeutics N.V. and Lava Therapeutics B.V. His work has been instrumental in advancing therapeutic strategies in immunology and oncology.

Collaborations

Lameris has collaborated with esteemed colleagues, including Johannes Jelle Van Der Vliet and Tanja Denise De Gruijl. These partnerships have further enriched his research and development efforts in the field of antibody technology.

Conclusion

Roeland Lameris stands out as an influential inventor in the biotechnology sector, with a focus on antibody innovations that have the potential to transform treatment approaches for various diseases. His contributions continue to shape the future of immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…